Device / Technology News

RSS

Cook Medical enrolls first patient in Formula PTX Balloon Expandable Renal Stent trial

Angiotech Pharmaceuticals, Inc. today announced Cook Medical, a license holder of Angiotech's paclitaxel technology, has enrolled the first patient in its landmark Formula PTX clinical trial. The trial is the first of its kind to evaluate the safety and effectiveness of a paclitaxel-eluting stent to treat renal artery disease, the narrowing of the arteries that supply blood to the kidneys.

22 Apr 2010

Legal case asks who to blame for medical device failure

The New York Times: A legal case now pending asks a question increasingly faced by the medical world -- "who should be held accountable when a company sells a flawed product that can injure or kill patients? Is it the company or the people who run it?"

22 Apr 2010

Health record push lacks FDA oversight, risks safety problems

The Huffington Post Investigative Fund: "As federal officials encourage the rapid expansion of electronic medical records to help doctors improve care and cut costs, they lack a reliable and systematic method for tracking the safety of these products, agency data and audits show. Instead, the Food and Drug Administration depends on a spotty warning system that can take a year to flag serious computer malfunctions and other software glitches.

22 Apr 2010

Positive results from initial clinical trial of ClariVein catheter

Results from the initial clinical trial of the ClariVein® catheter, used in a new minimally invasive treatment for varicose veins, have been announced. The device combines mechanical and chemical modalities to accomplish vein treatment in an in-office setting.

22 Apr 2010

Online Wiki offers information, comfort and community for families facing autism transition

Among the many challenges families caring for individuals with autism spectrum disorders face, perhaps the most difficult of all arrive "when the school bus stops." When a child with autism ages out of systems and supports designed for those up to ages 18-21, families face the daunting challenge of finding new resources and creating new communities for their children. Unfortunately, finding necessary services and supports can be very difficult.

22 Apr 2010

FDA approves Medtronic's Complete SE Vascular Stent System for PAD

Broadening the scope of innovation for cardiovascular interventions beyond the heart, Medtronic, Inc., announced today that it has received approval from the U.S. Food and Drug Administration (FDA) for the Complete® SE Vascular Stent System to be used for the treatment of peripheral arterial disease (PAD) in the iliac arteries, major blood vessels within the pelvis that supply blood to the lower extremities.

21 Apr 2010

Labopharm launches INTELLITAB abuse and misuse-deterrent technology platform

Labopharm Inc. today introduced INTELLITAB(TM), the brand name for its proprietary abuse and misuse-deterrent technology platform. The INTELLITAB(TM) platform, which can deliver one or more therapeutic drugs in combination over periods of up to 24 hours, has the potential to provide a patient with a controlled release medication while minimizing the risk of intentional abuse or accidental misuse.

21 Apr 2010

BIO-key International, Healthcare-ID to present biometric identity solutions at 56th CBBS Annual Meeting

BIO-key International, Inc., a leader in finger-based biometric identification solutions, today announced that BIO-key and its partner, Healthcare-ID, a leader in automated donor management solutions, will jointly participate at the 56th Annual Meeting of the California Blood Bank Society in BOOTH #123.

21 Apr 2010

CDI's iCell Cardiomyocytes named to MIT Technology Review's Annual 10 Emerging Technologies List

Cellular Dynamics International (CDI) today announced that CDI's development and commercialization of human cardiomyocytes for drug discovery and toxicity testing, based on the work of CDI co-founder and chief scientific officer, James A. Thomson, Ph.D., on induced pluripotent stem cell (iPSCs) technology, have been named to the MIT Technology Review's Annual 10 Emerging Technologies List.

21 Apr 2010

Sonic Innovations wins Best in Show award at AudiologyNOW! conference

Sonic Innovations, Inc. received a Best in Show award based on attendees' votes at the AudiologyNOW! conference for its tradeshow booth. The conference was held April 14 through 17 in San Diego, California and was attended by nearly 7,000 hearing care professionals.

21 Apr 2010

NCGR deploys Isilon scale-out NAS to power genome sequencing research services

Isilon Systems today announced that the National Center for Genome Resources has deployed Isilon scale-out NAS to power its full range of next-generation genome sequencing research services. By combining Isilon's X-Series, Backup Accelerator and CommVault's Simpana backup software, NCGR has unified eight Illumina Genome Analyzers onto a highly reliable, central storage resource, accelerating time-to-results and ensuring its research information is secure and accessible 24x7x365.

21 Apr 2010

Biomagnetics Diagnostics receives commitment for clinical validation testing in India for malaria, TB diagnosis

Biomagnetics Diagnostics Corp., a developer of revolutionary diagnostic systems and technology for HIV, hepatitis, tuberculosis and malaria detection, today announced it has received important commitments from two leading research laboratories in India for clinical validation testing for malaria and tuberculosis (TB) detection and diagnosis.

21 Apr 2010

New method to analyze molecular activity of cancer drugs for solid tumors using skin biopsies

A research team today reported clinical results of a new method for analyzing the molecular activity of cancer drugs for solid tumors using skin biopsies. The approach, enabled by Cambridge Research & Instrumentation, Inc.'s imaging and analysis systems, was presented in a poster session at the American Association of Cancer Research's Annual Meeting in Washington D.C.

21 Apr 2010

Alchemia’s HyACT tumour targeting technology enhances killing of cancer stem cells

Alchemia's subsidiary Alchemia Oncology today presented two posters at the American Association of Cancer Research (AACR) 101st Annual Meeting in Washington, DC. The data demonstrates the ability of the Company's HyACT tumour targeting technology to dramatically enhance the killing of cancer stem cells. These cells are highly resistant to treatment with chemotherapeutic drugs and are believed to be responsible for treatment failure and disease recurrence.

21 Apr 2010

Study assesses use of eMedonline to help manage patients' compliance with Gleevec

A clinical study underway at Rex Cancer Center of Wakefield will evaluate the use of telemonitoring in managing administration of Gleevec, a drug developed and manufactured by Novartis to treat chronic myeloid leukemia.

21 Apr 2010

Touch Bionics wins Queen's Awards for Enterprise in Innovation category for 2010

Touch Bionics, developer of advanced upper-limb bionic technologies, today announced it is a winner of the prestigious Queen's Awards for Enterprise with an award in the Innovation category for 2010. The Queen's Awards for Enterprise are the UK's most prestigious awards for business performance.

21 Apr 2010

Clarient Insight Dx Pulmotax assay helps predict response to chemotherapy in lung cancer patients

Clarient, Inc., a premier technology and services resource for pathologists, oncologists and the pharmaceutical industry, today announced that data from a new study suggest that the Clarient Insight® Dx Pulmotax™ assay may effectively predict which lung cancer patients will respond favorably to chemotherapy. The study, titled "TLE3 expression is predictive of response to chemotherapy in NSCLC," included 368 samples from carcinoma patients.

21 Apr 2010

New self-referencing glutamate biosensor to measure glutamate flux of neural cells in living organism

A new biosensor developed at Purdue University can measure whether neurons are performing correctly when communicating with each other, giving researchers a tool to test the effectiveness of new epilepsy or seizure treatments.

21 Apr 2010

Covidien's second-quarter medical devices sales up 11%

Covidien plc today reported results for the second quarter of fiscal 2010 (January - March 2010).

21 Apr 2010

Immunomedics' blood assay for PAM4-protein can detect pancreatic cancer and predict early relapse

Immunomedics, Inc., a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, today reported that a new blood test using the Company's proprietary humanized antibody, clivatuzumab or PAM4, predicted a partial response in an initial set of patients treated with a combination of the antibody labeled with yttrium-90 (Y-90) and gemcitabine. Results were presented at the 101st Annual Meeting of the American Association for Cancer Research.

21 Apr 2010

Device / Technology News

Cook Medical enrolls first patient in Formula PTX Balloon Expandable Renal Stent trial

Legal case asks who to blame for medical device failure

Health record push lacks FDA oversight, risks safety problems

Positive results from initial clinical trial of ClariVein catheter

Online Wiki offers information, comfort and community for families facing autism transition

FDA approves Medtronic's Complete SE Vascular Stent System for PAD

Labopharm launches INTELLITAB abuse and misuse-deterrent technology platform

BIO-key International, Healthcare-ID to present biometric identity solutions at 56th CBBS Annual Meeting

CDI's iCell Cardiomyocytes named to MIT Technology Review's Annual 10 Emerging Technologies List

Sonic Innovations wins Best in Show award at AudiologyNOW! conference

NCGR deploys Isilon scale-out NAS to power genome sequencing research services

Biomagnetics Diagnostics receives commitment for clinical validation testing in India for malaria, TB diagnosis

New method to analyze molecular activity of cancer drugs for solid tumors using skin biopsies

Alchemia’s HyACT tumour targeting technology enhances killing of cancer stem cells

Study assesses use of eMedonline to help manage patients' compliance with Gleevec

Touch Bionics wins Queen's Awards for Enterprise in Innovation category for 2010

Clarient Insight Dx Pulmotax assay helps predict response to chemotherapy in lung cancer patients

New self-referencing glutamate biosensor to measure glutamate flux of neural cells in living organism

Covidien's second-quarter medical devices sales up 11%

Immunomedics' blood assay for PAM4-protein can detect pancreatic cancer and predict early relapse

How can super-resolution technology help study neurotransmission?

The Proteoform Puzzle: Unlocking the Next Frontier

Synthetic Biology and the Pursuit of Living Diagnostics

Latest News